Improving the efficacy of antibody-based cancer therapies

Nature Reviews Cancer

Volumn 1, Issue 2, 2001, Pages 118-129

  Carter, Paul ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CANCER ANTIBODY; CYTOKINE; HYBRID PROTEIN; IMMUNOTOXIN; LIPOSOME; MONOCLONAL ANTIBODY; PRODRUG; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PASSIVE IMMUNIZATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS; LIPOSOMES; MICE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PRODRUGS; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035524114     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35101072     Document Type: Article

References (16)

1. Quan, M. P. & Carter, P. in Lung Biology in Health and Disease (eds Jardieu, P. M. & Fick, R. Jr) (Marcel Dekker, New York, 2001).
2. Glennie, M. J. & Johnson, P. W. Clinical trials of antibody therapy. Immunol. Today 21, 403-410 (2000).
3. Hoogenboom, H. R. & Chames, P. Natural and designer binding sites made by phage display technology. Immunol. Today 21, 371-378 (2000).
4. Little, M., Kipriyanov, S. M., Le Gall, F. & Moldenhauer, G. Of mice and men: hybridoma and recombinant antibodies. Immunol. Today 21, 364-370 (2000).
5. Halin, C. & Neri, D. Antibody-based targeting of angiogenesis. Crit. Rev. Ther. Drug Carrier Syst. 18, 299-339 (2001).
6. Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
7. McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1993). Pivotal Phase III trial that led to the approval of Rituxan for the treatment of low-grade or follicular non-Hodgkin's lymphoma.
8. HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
9. Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639-2648 (1999).
10. Yang, X. D. et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999).
11. Agus, D. B. et al. A potential role for activated HER-2 in prostate cancer. Semin. Oncol. 27, 76-83 (2000).
12. Fitzpatrick, V. D., Pisacane, P. I., Vandlen, R. L. & Sliwkowski, M. X. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 431, 102-106 (1998).
13. Pietras, R. J. et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogens 9, 1829-1838 (1994).
14. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A. & Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogens 17, 2235-2249 (1998).
15. Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998).
16. Pegram, M. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241-2251 (1999).